Trilaciclib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Trilaciclib. Educational only — not medical advice.
Labeled uses
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Source: FDA labeling via NIH DailyMed (set 4b06922c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.